DEVICE DTC
agency: BBDO
brand: Cypher
client: Cordis, a Johnson & Johnson company Agency team names withheld at client's request
A drug-eluding stent isn't something that's typically considered "patient's choice," so it seems counterintuitive to create consumer print ads to promote them. But to the surprise of industry watchers, that's just what BBDO did. Check out the agency's eye-catching campaign for Johnson & Johnson's Cypher stent, launched as full-page spreads in magazines and newspapers beginning in October 2007.
The spots feature people engaging in everyday physical activities, from jogging to playing with children. They also show the actual size of a stent and offer risk-and-benefit information. We like these ads because they educate consumers in an area where most say they don't need to be educated—and that's just nonsense. "It's up to the doctor to determine what's best for the patient, but we wanted to make sure the information was out there," said Cordis' Carol Goodrich, director of corporate communications. "It really is all about physician and patient interaction and conversation about coronary-artery disease."
PREVIOUS AGENCY ‹‹ HOME ›› NEXT AGENCY
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.